Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) FCF Margin (2016 - 2025)

Historic FCF Margin for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 4.26%.

  • Harvard Bioscience's FCF Margin rose 121000.0% to 4.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.52%, marking a year-over-year increase of 76500.0%. This contributed to the annual value of 1.28% for FY2024, which is 121800.0% down from last year.
  • Per Harvard Bioscience's latest filing, its FCF Margin stood at 4.26% for Q3 2025, which was up 121000.0% from 13.04% recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's FCF Margin ranged from a high of 16.34% in Q3 2023 and a low of 8.54% during Q1 2022
  • Its 5-year average for FCF Margin is 3.49%, with a median of 3.28% in 2021.
  • In the last 5 years, Harvard Bioscience's FCF Margin tumbled by -241800bps in 2024 and then surged by 202400bps in 2025.
  • Quarter analysis of 5 years shows Harvard Bioscience's FCF Margin stood at 0.73% in 2021, then soared by 1279bps to 8.6% in 2022, then surged by 43bps to 12.34% in 2023, then tumbled by -53bps to 5.8% in 2024, then fell by -27bps to 4.26% in 2025.
  • Its FCF Margin was 4.26% in Q3 2025, compared to 13.04% in Q2 2025 and 11.36% in Q1 2025.